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Methamphetamine is one of the most popular recreational drugs in Central Europe and 
is often combined with ethanol. Various interactions between these two substances have 
been described including the influence of administered ethanol on biotransformation 
of methamphetamine. The aim of the present study was to describe the opposite effect – 
the influence of methamphetamine on biotransformation of ethanol in rats. 
Methamphetamine was administered for 10 days (10 mg/kg/day) i.p. and ethanol was 
delivered as an intragastric bolus (2 g/kg) on the10th day of experiment to both 
methamphetamine administered rats and control animals. The pharmacokinetic 
experiment on the whole animal was performed and plasma samples were drawn 
at the 40th, 120th, 210th and 300th minute after ethanol administration. 
Ethanol plasmatic levels reached significantly lower values in the 40th and 120th interval 
when compared to controls. Differences were insignificant in the last two intervals. 
Our results suggest that chronic methamphetamine administration induces ethanol 
biotransformation. We suppose that this effect is caused by induction of alcohol 
dehydrogenase metabolic activity or by allosteric interaction of methamphetamine and 
this enzyme. More studies have to be conducted to confirm or disprove our hypothesis. 
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INTRODUCTION 
 
Substance abuse is as old as mankind, and brings together health and social problems 
affecting both the abuser and the society as well. Drugs of abuse are miscellaneous 
substances eliciting different biologic effects, and their misuse is usually region-specific 
due to differences in their availability, legislation, and social conditions in the specific 
area. One of the most popular recreational drugs besides cannabis in the Central Europe 
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is methamphetamine (METH). METH abuse in the Czech Republic has a long tradition, 
as amphetamines serving as a substrate for METH production were available in this 
region till late 1980s whereas in other European countries were restricted in 1970s. 
In fact, the Czech Republic is the leader in prevalence of METH users, and the number 
of dependent individuals stays consistent for many years (EMCDDA 2010). 
The combinations of recreational drugs are usual in drug abusers, and ethanol (ET) 
as a legal substance is often consumed by addicted people. Combining ET with other 
substances can lead to severe pharmacokinetic or pharmacodynamic interactions. 
Actually, the most frequent combinations of drugs that lead to visit of the Emergency 
Department in U.S. in 2008 were those with ET (SAMHSA 2008). 
The interactions between METH and ET have been widely studied. The experiments 
focused on the behavioural aspects of  ET and METH combination documented, that ET 
accentuates the METH neurotoxicity, and both of them are evoking anxiolytic effects 
in rats (Chuang et al., 2011). The combination is also more potent in causing memory 
impairment in rats than administration of single drugs (Yamamura et al., 1992). 
The molecular mechanism of these behavioural effects is probably carried by different 
changes on dopamine and serotonin release, which are dependent not only 
on the substance, but may also vary between rat strains (Nishiguchi et al., 2002, 
Yamauchi et al., 2000). The chronic administration of METH alone could increase 
the ET intake in mice because of induction of long term dopaminergic toxicity, and 
hypodopaminergic state is described to increase the voluntary ET consumption 
(Gutierrez-Lopez et al., 2010).  
 
Preclinical experiments aimed on pharmacokinetic interactions of ET and METH 
describe the inhibition of METH metabolism when combined with ET (Liang et al., 
2012). Increase in the METH plasmatic levels is due to inhibition of METH N-
demethylation and parahydroxylation (Yamada et al., 2001) caused by ET. The similar 
result was confirmed in humans, too (Shimosato, 1988), whereas other clinical trial 
with ET and METH combination did not discover any change in METH levels among 
subjects (Mendelson et al., 1995). The design of the study can substantially influence 
results, since it was described that coincidental administration of ET and METH results 
in inhibition of METH metabolism, whereas the same substance is biotransformed faster 
in METH addicts with chronic ET ingestion (Shimosato et al., 1988). 
Papers describing pharmacokinetic interaction between METH and ET are exclusively 
aimed on the influence of ET on the biotransformation of METH, while our recent study 
is addressed oppositely. We have determined the effect of 10 day long METH 
administration on the pharmacokinetics of ET in rats. We hypothesised that ET 
plasmatic levels could be influenced due to inhibitory effect of METH on cytochrome 
P450 2E1 enzyme, which was documented (Minarikova et al., 2006). Therefore we 
decided to use a relatively high but equal dose of METH as was administered 
in Minarikova’s study.  
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MATERIAL AND METHODS 
 
Animals 
The study was carried out on male Wistar albino rats weighing 200±20 g. Animals were 
housed under temperature (21-22°C) and humidity (50-60 %) controlled conditions. 
Rats were housed singly to avoid injuries in METH administered individuals in standard 
plastic cages with free access to water and pelleted diet.  
Animals were randomly divided into two groups (n=10), one of them was administered 
with intraperitoneal injections of METH (Sigma Chemical Co., St. Louis, USA) at one 
daily dose of 10.0 mg/kg for 10 consecutive days. Second group – controls, received 
equal volume of saline. 
All procedures were approved by the Czech Central Commission for Animal Welfare. 
 
Pharmacokinetic study 
The pharmacokinetic study in the whole animal was performed on the 10th day 
of METH treatment. The animals were injected either with METH or saline, and 
consecutively with ET intragastrically. ET (Lach-Ner s.r.o., Neratovice, CZ) was 
administered at the dose of 2.0 g/kg as a 20% solution dissolved in 5% glucose, to limit 
the gastric irritation and supply rats with additional nutrition for the kinetic experiment. 
Animals were anesthetized with diethylether, and blood from plexus retrobulbaris was 
sampled with heparinized capillary tube in the following time intervals from ET 
administration: 40 min, 120 min, 210 min, and 300 min. Samples were allowed to clot 
at room temperature and were centrifuged 10 minutes at 4°C at 3000 g to obtain serum, 
which was frozen until analysis at - 75°C. 
 
Sample analysis 
Gas chromatography (GC) was used to evaluate the levels of ET in samples. Analysis 
was performed on YL 6100GC (YL Instruments Co., Kyounggi-do, KOR) with Agilent 
5062-3587 (Agilent Technologies Int., Santa Clara, USA) inlet, flame ionization 
detector and SLB-5ms 30 m x 0.25 mm x 0.25 µm (Sigma Chemical Co., St. Louis, 
USA) column. Analysis conditions were as follows: carrier gas nitrogen, inlet 
temperature 160°C; flow 2 ml/min; split 1:30; detector temperature 200°C, gas flow – 
air 300 ml, hydrogen 30 ml, make up 20 ml; total separation time 6.5 min. Limit 
of detection and quantification was determined to be 0.006‰ and 0.009‰ 
of ET respectively. The samples were analysed in duplicates and the mean value was 
used for the statistical analysis. The calibration line was transformed into log line 
for the values close to the quantification limit. 
 
Statistical evaluation 
Obtained results were statistically analysed with Dixon’s Q test to exclude outliers. 
Repeated measure ANOVA with Fisher post-hoc test for multiple comparisons was 
used for the data analysis using software Statistica 8 for Windows. Data are expressed 
as means ± SD. Values of p<0.05 were considered to be statistically significant. 
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RESULTS 
 
The levels of ET measured declined in both METH and saline treated groups 
during the experiment (Figure 1), but there were statistically significant differences 
between the values in the first two sampling intervals. The plasmatic levels of ET in rats 
which received METH were lower than in controls. In the 40th minute ET values 
in METH animals were 0.594‰, SD ± 0.303‰, while in the control group animals 
1.618‰, SD ± 0.696‰; p<0.001. In the 120th min in METH animals were measured 
values 0.189‰, SD ± 0.169‰, in comparison to controls 0.853‰, SD ± 0.665‰; 
p=0.002. There were no statistically significant differences in the last two intervals 
assessed. ET concentration in the 210th were METH 0.010‰, SD ± 0.005‰, control 
0.331‰, SD ± 0.447‰, p= 0.31. In METH animals 0.007‰, SD ± 0.001 ‰ and 
in control rats 0.014‰, SD ± 0.014‰ was detected. 
  
 
Figure 1. Ethanol concentrations [‰] in controls and rats administered 
with methamphetamine (10 mg/kg/day) for 10 days after single dose 
of ethanol (2 g/kg). Data represents means ± SD 
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DISCUSSION 
 
Our results did not confirm our original hypothesis of ET metabolism inhibition 
due to influence of METH on 2E1 enzyme. Oppositely, obtained data suggests that 
chronic administration of METH increased the rate of ET biotransformation. This was 
apparent from the lower concentrations of ET in METH administered animals than 
in controls. However, the METH influence was statistically significant only in the first 
two sampling intervals. Thus, we suppose that insignificancy of difference between 
groups in samples drawn on the 210th and 300th minutes rise from very low ET level 
reaching almost the detection limit of method used. As far as we know, induction of ET 
biotransformation by METH was not described previously unlike of opposite effect of 
ET on METH metabolism (Liang et al., 2012, Mendelson et al., 1995, Shimosato, 1988, 
Shimosato et al., 1988, Yamada et al., 2001). 
We suggest that there may be considered three possible mechanisms explaining the 
pharmacokinetic interaction described: 1. METH decreases the bioavailability of ET; 2. 
METH enhances the excretion of unchanged ET; 3. METH induces enzymes of ET 
biotransformation pathway.  
Most of the interactions on the level of absorption are based in the change of specific 
carrier system activity and thus occur only in drugs using this mechanism of absorption. 
ET with small molecule and its physico-chemical properties is an easily diffusible 
compound (Holt, 1981) crossing well all biological barriers in the body. Therefore the 
first above-mentioned suggestion can be excluded and because of the same reasons 
the second one as well. The portion of unchanged ET excreted by  lungs and kidneys 
varies from 2 to 10% (Lieber, 1997) and no specific carriers are involved. 
The third possible explanation: it has to be considered that approximately 89% 
of METH is metabolized in rats with major metabolites 4-hydroxymethamphetamine 
and 4-hydroxynorephedrine (Caldwell et al., 1972). The enzymes involved in the 
metabolism of METH are cytochromes P450 (CYP), especially CYP2D enzymes 
participating in 4-hydroxylation of METH aromatic ring (Lin et al., 1995). 
While the major metabolic pathway of ET in rats is via alcohol dehydrogenase (ADH) 
with essential role of ADH-3 isoenzyme (Boleda et al., 1989), the ADH is not the only 
enzyme metabolizing ET. The minor metabolic pathway of ET microsomal oxidizing 
system represents CYP2E1 (Ronis et al., 1993). Further, it is known, that CYP2E1 is 
inducible and the observed effect of METH could be explained by massive increase 
of CYP2E1 metabolic rate. However, the induction of this enzyme is described 
for ethanol (McGehee et al., 1994) but not for METH. The influence of METH on CYP 
enzymes is disputable. There are works describing induction of CYP2D, CYP2C6 and 
CYP3A by METH (Dostalek et al., 2005, 2007). Nevertheless we did not document this 
effect in our previous studies (Zendulka et al., 2010). Same result is reported 
by Minarikova; moreover she documented a weak inhibitory effect of METH 
on CYP2E1 (Minarikova et al., 2006). This means that the induction of ET metabolism 
is definitely not carried by the effect of METH on CYP and thus only the possibility 
of ADH induction remains. The increase of ADH activity can be either in post-
translational phase by allosteric activation by METH or by genetic transcription 
stimulation. The question whether it is caused directly by METH or indirectly via 
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dopaminergic activity of METH in the CNS and its peripheral consequences is still not 
answered. More studies have to be conducted to confirm or disprove our hypothesis.  
 
 
CONCLUSIONS 
 
Taken together, our results suggest that repeated pre-treatment with METH led 
to the decrease of ET levels in time points between minutes 0 and 120 after acute 
alcohol administration. According to the best of our knowledge such effect was not 
described before. Thus our next study will be focused on dose dependence in the actual 
documented effect of METH on ET metabolism. 
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Metamfetamin je jednou z nejčastěji zneužívaných drog v regionu Střední Evropy a velmi často je 
jeho užívání kombinováno s požíváním alkoholu. V minulosti byly popsány rozličné interakce 
mezi těmito dvěma látkami včetně vlivu ethanolu na biotransformaci metamfetaminu. Cíl této 
práce je přesně opačný, tedy popsat vliv metamfetaminu na biotransformaci etanolu u potkana. 
Metamfetamin (10 mg/kg/den) byl zvířatům aplikován ve formě i.p. injekcí 10 dní. Ethanol (2 
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g/kg intragastricky) byl podán kontrolním i metamfetaminem premedikovaným zvířatům společně 
s poslední dávkou metamfetaminu. Následně byl proveden farmakokinetický experiment na celém 
zvířeti s odběrem vzorků krve v následujících časových intervalech od aplikace ethanolu: 40, 120, 
210 a 300 minut.  
Hladiny ethanolu v plazmě stanovené metodou plynové chromatografie byly signifikantně nižší 
u metamfetaminem premedikovaných zvířat než u kontrol ve 40. a 120. minutě experimentu, 
zatímco v následujících dvou časových intervalech byl rozdíl nesignifikantní. Naše výsledky 
naznačují, že chronicky aplikovaný metamfetamin zrychluje biotransformaci ethanolu. 
Domníváme se, že tento efekt je zprostředkován prostřednictvím alkoholdehydrogenázy 
buď zvýšení genové exprese nebo alosterickou modulací tohoto enzymu vlivem metamfetaminu. 
K ověření nebo vyvrácení naší hypotézy je nutné provést další studie.  
 
 
Acta Fac. Pharm. Univ. Comen. LIX, 2012, (2), p. 63-71. 
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